Skip to content
AssessmentInteractive prototype

Practice Health Check

Score eight signals across revenue cycle, payer mix, referral concentration, authorization performance and infusion economics.

Illustrative assumptions. Default values here are example inputs for demonstration only — not validated reimbursement rates, costs or benchmarks. Replace every field with your own practice’s figures.

Revenue cycle
days

Typically longer in drug-heavy practice because high-value claims attract more review.

%

By dollars, not count. In infusion practice a count-based rate materially understates exposure.

%

What you collected against what you were contractually entitled to collect.

%

Where authorisation and drug-claim problems accumulate first.

Payer mix
%

In drug-heavy practice a single payer's policy change can move your margin on its own.

Referral concentration
%

The share of new patients arriving from your single biggest referring institution or physician.

Authorization performance
days

The single interval that captures coverage, authorisation, access, pharmacy, nursing and communication at once.

Infusion economics
%

Contribution after drug acquisition, nursing and coordination, as a share of infusion revenue.

Scoring bands in this prototype are illustrative reference points chosen to demonstrate the mechanism — they are not licensed benchmark data. A production version would score against validated, sourced benchmarks appropriate to infectious disease practices of your size and payer mix, with the methodology published.

Practice health score

50OUT OF 100

Under pressure

A weighted read across 8 signals in 5 categories. The score is a prompt to look somewhere specific — not a grade.

By category

Revenue cycle50 · Watch

Days in A/R 67.5 days · Denial rate by dollars 11% · Net collection rate 91% · A/R over 90 days 26%

Payer mix50 · Watch

Largest single payer share 47.5%

Referral concentration50 · Watch

Largest referral source share 42.5%

Authorization performance50 · Watch

Median referral to first dose 7 days

Infusion economics50 · Watch

Infusion contribution margin 17.5%

Start here

A/R over 90 days · Revenue cycle

Segment by payer and by drug — concentration in one agent usually means a criteria or coding problem.

Read the ID revenue-cycle guidance
Weighted score
50 / 100
Band
Under pressure
Signals below adequate
8 of 8
Strongest category
Revenue cycle

Nothing you enter here is transmitted or stored. The calculation runs entirely in your browser.

How this is calculated

  • Each of eight signals is scored 0–100 by linear interpolation between a 'strong' and a 'weak' reference point.
  • Signals are grouped into categories — revenue cycle, payer mix, capacity, staffing, and for ID referral concentration, authorization performance and infusion economics — and each category is scored on its own.
  • Categories are weighted and combined into a single practice score; net collection rate and denial rate carry the most weight.
  • The 'start here' recommendation is the signal with the lowest weight-adjusted score, not the lowest raw score.

What it does not do

  • The reference points are illustrative demonstration values, not licensed benchmarks. A production version would score against validated, sourced data with published methodology.
  • It cannot distinguish a definitional difference (gross vs net days in A/R) from a real performance difference.
  • A score is a prompt to look somewhere specific. It is not a grade, and it is not a diagnosis.

Now that you have a number

Want to understand what's driving your score?

A score tells you where to look. Persistex helps independent infectious disease practices identify revenue-cycle opportunities and the operational inefficiencies behind them — working from your real data rather than from estimates.

Prototype: these routes to a demonstration form. No data is transmitted or stored.